Cargando…

Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED‐HF study

AIMS: To test the prognostic value of emerging biomarkers in the Reduction of Events by Darbepoetin Alfa in Heart Failure (RED‐HF) trial. METHODS AND RESULTS: Circulating cardiac [N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP), and high‐sensitivity troponin T (hsTnT)], neurohumoral [mid‐regio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Welsh, Paul, Kou, Lei, Yu, Changhong, Anand, Inder, van Veldhuisen, Dirk J., Maggioni, Aldo P., Desai, Akshay S., Solomon, Scott D., Pfeffer, Marc A., Cheng, Sunfa, Gullestad, Lars, Aukrust, Pål, Ueland, Thor, Swedberg, Karl, Young, James B., Kattan, Michael W., Sattar, Naveed, McMurray, John J.V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2017
Materias:	Biomarkers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607475/ https://www.ncbi.nlm.nih.gov/pubmed/28960777 http://dx.doi.org/10.1002/ejhf.988

Ejemplares similares

Growth differentiation factor 15 predicts poor prognosis in patients with heart failure and reduced ejection fraction and anemia: results from RED-HF
por: Ueland, Thor, et al.
Publicado: (2021)

Pro‐gastrin‐releasing peptide and outcome in patients with heart failure and anaemia: results from the RED‐HF study
por: Ueland, Thor, et al.
Publicado: (2018)

Relationship between outdoor temperature and cardiovascular disease risk factors in older people
por: Sartini, Claudio, et al.
Publicado: (2016)

Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS‐HF and RALES
por: Yeoh, Su E., et al.
Publicado: (2021)

Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: The NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial
por: Maisel, Alan S., et al.
Publicado: (2011)

Prevalence and prognostic implication of iron deficiency and anaemia in patients with severe aortic stenosis
por: Kvaslerud, Anette Borger, et al.
Publicado: (2018)

Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON‐HF
por: Mooney, Leanne, et al.
Publicado: (2021)

Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON‐HF trial
por: Chatur, Safia, et al.
Publicado: (2022)

Dipeptidyl peptidase 3, a marker of the antagonist pathway of the renin–angiotensin–aldosterone system in patients with heart failure
por: Boorsma, Eva M., et al.
Publicado: (2021)

Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM‐HF trial
por: Vardeny, Orly, et al.
Publicado: (2016)

The role of cathepsin D in the pathophysiology of heart failure and its potentially beneficial properties: a translational approach
por: Hoes, Martijn F., et al.
Publicado: (2019)

The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction
por: Stahrenberg, Raoul, et al.
Publicado: (2010)

Risk of bias in studies investigating novel diagnostic biomarkers for heart failure with preserved ejection fraction. A systematic review
por: Henkens, Michiel T.H.M., et al.
Publicado: (2020)

Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM‐HF trial
por: Vardeny, Orly, et al.
Publicado: (2019)

Relationship between duration of heart failure, patient characteristics, outcomes, and effect of therapy in PARADIGM‐HF
por: Yeoh, Su E., et al.
Publicado: (2020)

Distinct patterns of soluble leukocyte activation markers are associated with etiology and outcomes in precapillary pulmonary hypertension
por: Lekva, Tove, et al.
Publicado: (2020)

Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials
por: Wijkman, Magnus O., et al.
Publicado: (2022)

Immediate response in markers of inflammation and angiogenesis during exercise: a randomised cross-over study in heart transplant recipients
por: Yardley, Marianne, et al.
Publicado: (2017)

Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
por: Docherty, Kieran F., et al.
Publicado: (2022)

Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF
por: Yeoh, Su Ern, et al.
Publicado: (2023)

Microvascular function and inflammatory activation in Takotsubo cardiomyopathy
por: Solberg, Ole Geir, et al.
Publicado: (2023)

Dementia‐related adverse events in PARADIGM‐HF and other trials in heart failure with reduced ejection fraction
por: Cannon, Jane A., et al.
Publicado: (2016)

Serum potassium in the PARADIGM‐HF trial
por: Ferreira, João Pedro, et al.
Publicado: (2020)

Effect of sacubitril/valsartan on investigator‐reported ventricular arrhythmias in PARADIGM‐HF
por: Curtain, James P., et al.
Publicado: (2022)

Similar dysregulation of lupus-associated miRNAs in peripheral blood mononuclear cells and splenic lymphocytes in MRL/lpr mice
por: Wang, Zhuang, et al.
Publicado: (2018)

Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM‐HF trial
por: Bhatt, Ankeet S., et al.
Publicado: (2021)

Homoarginine, heart failure, and sudden cardiac death in haemodialysis patients
por: Drechsler, Christiane, et al.
Publicado: (2011)

Plasma tissue inhibitor of matrix metalloproteinase-1 (TIMP-1): an independent predictor of poor response to cardiac resynchronization therapy
por: Tolosana, Jose María, et al.
Publicado: (2010)

Circulating microRNAs for predicting and monitoring response to mechanical circulatory support from a left ventricular assist device
por: Morley-Smith, Andrew C, et al.
Publicado: (2014)

Test-Retest Reliability of Diffusion Tensor Imaging in Huntington’s Disease
por: Cole, James H., et al.
Publicado: (2014)

Carbamylated vimentin represents a relevant autoantigen in Latin American (Cuban) rheumatoid arthritis patients
por: Martínez, Goitybell, et al.
Publicado: (2016)

Quantification of the Light Subunit of Neurofilament Protein in Cerebrospinal Fluid of Huntington’s Disease Patients
por: Szejko, Natalia, et al.
Publicado: (2018)

Natriuretic Peptides in Chronic Heart Failure
por: Brunner-La Rocca, Hans-Peter, et al.
Publicado: (2019)

Biomarkers in Routine Heart Failure Clinical Care
por: Nadar, Sunil K, et al.
Publicado: (2019)

Variability of biomarkers in patients with chronic heart failure and healthy controls
por: Meijers, Wouter C., et al.
Publicado: (2016)

Urinary peptide-based classifier CKD273: towards clinical application in chronic kidney disease
por: Pontillo, Claudia, et al.
Publicado: (2017)

Clinical proteomics in kidney disease as an exponential technology: heading towards the disruptive phase
por: Sanchez-Niño, Maria Dolores, et al.
Publicado: (2017)

The clinical utility of kinetic glomerular filtration rate
por: O'Sullivan, Eoin D., et al.
Publicado: (2017)

Serum levels of selected cytokines [interleukin (IL)-17A, IL-18, IL-23] and chemokines (RANTES, IP10) in the acute phase of immunoglobulin A vasculitis in children
por: Jaszczura, Majka, et al.
Publicado: (2019)

Identifying and Characterizing Stress Pathways of Concern for Consumer Safety in Next-Generation Risk Assessment
por: Hatherell, Sarah, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_av9g4j1f76gvkd30urk3eekim5